David Dworaczyk, PhD: Utuly, a Non-needle Epinephrine Alternative Patients are Waiting for


There have been long stretches of time between the innovation of epinephrine delivery in the allergy space.

In an interview with HCPLive, Bryn Pharma's chief executive officer (CEO) David Dworaczyk, PhD, stated that the company’s novel intranasal epinephrine spray Utuly demonstrated a pharmacokinetic (PK) profile that was higher and more prolonged than that of the epinephrine autoinjector. He also said Utuly has now shown similar heart rate and blood pressure effects to an epinephrine autoinjector.

It was emphasized that the rapid absorption and PK profiles of the nasal delivery system are just as important as the form factor.

“We think that the nasal delivery systems, people want it, they would probably use it sooner, and they would use it faster,” he said. “But the key here is that it has to perform as well as the autoinjector to be able to make sure that the patient is in fact covered, and the assurance that they're getting to the therapeutic levels that they need as quickly as the EpiPen does.”

Market research revealed patients want an alternative, non-needle epinephrine delivery system.

“The actual package insert for epinephrine was actually prepared, I think it was in 1938 or 39, the next innovation was in 1987, and now we have the nasal delivery,” Dworaczyk said. “So there's been long stretches of time between innovation in the space.”

Related Videos
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
© 2024 MJH Life Sciences

All rights reserved.